Pulmatrix Merger with Eos to Hand 94% Control to Eos Shareholders; Eos CEO Takes 9.99% Stake
Summary
Kevin M. Slawin, CEO of Eos SENOLYTIX, Inc., has disclosed a 9.99% stake in Pulmatrix via convertible preferred stock, explicitly backing a planned merger between the two companies. This investment, detailed in a Schedule 13D filing, follows a recent $1 million private placement of Series B Convertible Preferred Stock. Crucially, the filing reveals that upon the merger's closing, Eos stockholders are expected to own approximately 94% of the combined entity, indicating severe dilution for existing Pulmatrix shareholders. This development significantly alters the company's future, shifting control and business focus to Eos, and represents a new direction compared to the reverse merger with Cullgen Inc. mentioned in the recent 10-K.
At the time of this announcement, PULM was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $1.16 to $9.37. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.